NCT04692831 - Testing a New Imaging Agent to Identify Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

HER-2 Positive Malignant Carcinoma of BreastHER-2 Protein OverexpressionHER2-positive Metastatic Breast Cancer

Interventions

COMBINATION_PRODUCT

89Zr-ss-pertuzumab PET/CT

Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre

11725

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack

92663

PATTY AND GEORGE HOAG CANCER CENTER (Data or Specimen Analysis Only), Newport Beach

07920

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER